Amyloid precursor protein–Tau interface (null)

The "amyloid precursor protein–Tau interface" represents a specific binding region where APP and Tau protein interact physically. Both proteins are centrally involved in Alzheimer’s disease pathology—APP is the precursor to amyloid-β (Aβ), and Tau forms neurofibrillary tangles. Experimental evidence suggests this interface may modulate the pathological progression of Alzheimer’s disease, potentially influencing both amyloid plaque accumulation and tau pathophysiology[1][2][4][6][8]. While the precise residues and structure of the interface remain under investigation, recent studies show that peptides mimicking APP1 (amino acids 390–412) and Tau1 (amino acids 19–34) can interact and that linked versions of these peptides, administered in vivo, inhibit APP–Tau interaction, reduce amyloid plaque burden, and protect against cognitive decline in mouse models of Alzheimer’s disease[4][8]. Targeting the APP–Tau interface is a novel therapeutic strategy under early investigation, but since it does not represent a single molecular entity like a receptor or enzyme but rather a protein–protein contact surface, it does not fall within traditional target classifications. No approved drugs are known to selectively target this interface; current approaches are preclinical, mostly focused on engineered peptides or small molecules to disrupt the protein interaction[4][8]. The specificity, long-term consequences, and translation of such interventions to humans remain active areas of research.

Other names

APP–Tau interfaceAmyloid precursor protein and Tau interaction siteAPP–Tau binding site

Inhibition of APP–Tau binding; Reduction of downstream amyloid plaque and tau tangle formation